Lineage Cell Therapeutics (LCTX) announced that 36-month results from patients enrolled in a Phase 1/2a clinical study of RG6501 in patients with geographic atrophy secondary to age-related macular degeneration, will be presented at Clinical Trials at the Summit, CTS, 2025. CTS will be held June 20 – 21, 2025, and brings together a diverse group of experts from around the world to discuss ongoing clinical trials and the latest data, all with the goal of achieving advances in vitreoretinal care. The presentation, “OpRegen Retinal Pigment Epithelium Cell Therapy for Patients with Geographic Atrophy: Month 36 Results from the Phase 1/2a Trial,” will be presented by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine, on behalf of Roche and Genentech, a member of the Roche Group.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX: